This article provides an overview of a market research report published by Blackridge Research & Consulting.
Report Overview
This market research report focuses on the key players and strategic dynamics within the global sodium-ion battery (SIB) market as of 2026. It analyzes the accelerating commercialization and adoption of SIBs across various applications, including electric vehicles (EVs), commercial vehicles, and stationary energy storage systems. The report offers insights into technological advancements, production capacities, and market shares, detailing how leading companies are addressing performance enhancement, cost reduction, and supply chain security for SIBs.
Key Findings
- CATL’s Market Leadership: Chinese battery giant CATL introduced its second-generation Naxtra sodium-ion battery in 2025, commencing mass production in December of that year. Naxtra is positioned at the forefront of the market, offering cost-effective solutions for EVs and energy storage systems, characterized by excellent environmental adaptability, rapid charging capabilities, and robust low-temperature performance.
- BYD’s Strategic Entry: BYD, another major Chinese player, announced plans for a 30 GWh capacity sodium-ion battery pilot production line in Xining, Qinghai, in July 2025. BYD aims for high low-temperature performance with this technology, expecting to retain 85% of capacity at -20°C, which would be a significant advantage for EV deployment in colder climates.
- Market Growth Drivers: The report identifies fluctuating lithium prices, the imperative for supply chain diversification, and increasing demands for safety and sustainability as primary drivers propelling the rapid growth of the sodium-ion battery market.
About the Publisher
Blackridge Research & Consulting is a firm that provides in-depth market research and consulting services across various global industries. They deliver data-driven insights and strategic analysis in sectors such as technology, energy, and automotive, assisting businesses in making informed decisions.

Comments